Macmillan Cancer Support’s Innovation Impact Investment Portfolio has made its first investment – with £100,000 for 52 North Health’s Neutrocheck.
Macmillan invests in Neutrocheck sepsis at-home testing
Macmillan Cancer Support’s Innovation Impact Investment Portfolio has made its first investment – with £100,000 for 52 North Health’s Neutrocheck.
